Iron oxide nano particles and its applications to cure HER2-positive mediated breast cancer

Breast cancer is the second leading cause of death in women worldwide. The extremely rapid rate of metastasis and the propensity to develop resistance to all non-traditional treatments make them equally difficult to treat, which are the causes of increased morbidity and death in breast melanoma patients. Experts all around the world have been focusing on the first detection of a breast lump so that action can be taken at the earliest possible time. Furthermore, traditional treatment procedures such as chemotherapy, radiation, and local surgical treatment suffer from a slew of drawbacks, including toxicity, normal cell genetic modification, and cancer cell spread to healthy tissues. As a result, new therapy regimens with little toxicity to normal cells must be developed very away. Iron oxide nanoparticles are still widely utilized for heat targeting and imaging of breast development cells. Using an external magnetic field, they can be coupled with medicines, proteins, enzymes, antibodies, or nucleotides and delivered to target organs, tissues, or malignancies. Both in vitro and in vivo, iron oxide nanoparticles have been found to be effective as theranostics treating breast cancer. Furthermore, their interactions with pharmaceuticals or functional biomolecules improve drug delivery efficiency and reduce drug systemic toxicity. The multipurpose presentations of superparamagnetic iron oxide nanoparticles on the analysis, behavior, and perceiving development of breast disease remedy are emphasized in this assessment. Because of their remarkable superparamagnetic, biocompatible, and biodegradable qualities, they are widely used.